Department of Internal Medicine.
Int J Womens Health. 2010 Aug 9;2:1-6.
Osteoporosis is a progressive and debilitating disease characterized by a massive bone loss with a deterioration of bone tissues, and a propensity for a fragility fracture. Strontium ranelate is the first antiosteoporotic treatment that has dual mode of action and simultaneously increases bone formation, while decreasing bone resorption, thus rebalancing bone turnover formation. Strontium ranelate rebalances bone turnover in favor of improved bone geometry, cortical thickness, trabecular bone morphology and intrinsic bone tissue quality, which translates into enhanced bone strength. This review describes the mechanism of the strontium ranelate action and its effects on bone mineral density, bone turnover, and osteoporotic fractures. The efficacy of strontium ranelate in postmenopausal osteoporosis treatment to reduce the risk of vertebral and hip fractures has been highlighted in several randomized, controlled trials. Treatment efficacy with strontium ranelate has been documented across a wide range of patient profiles: age, number of prevalent vertebral fractures, body mass index, and a family history of osteoporosis. Because strontium ranelate has a large spectrum of efficacy, it can be used to treat different subgroups of patients with postmenopausal osteoporosis. Strontium ranelate was shown to be relatively well tolerated and the safety aspects were good. Strontium ranelate should be considered as a first-line treatment for postmenopausal osteoporotic patients.
骨质疏松症是一种进行性和使人虚弱的疾病，其特征是大量骨质流失，骨组织恶化，容易发生脆性骨折。雷奈酸锶是第一种具有双重作用的抗骨质疏松药物，它可以同时增加骨形成，减少骨吸收，从而重新平衡骨转换形成。雷奈酸锶重新平衡骨转换，有利于改善骨几何形状、皮质厚度、小梁骨形态和内在骨组织质量，从而提高骨强度。本文描述了雷奈酸锶的作用机制及其对骨密度、骨转换和骨质疏松性骨折的影响。雷奈酸锶在绝经后骨质疏松症治疗中降低椎体和髋部骨折风险的疗效已在多项随机对照试验中得到证实。雷奈酸锶的治疗效果在广泛的患者人群中得到了证明：年龄、椎体骨折数量、体重指数和骨质疏松家族史。由于雷奈酸锶具有广泛的疗效，它可以用于治疗不同亚组的绝经后骨质疏松症患者。雷奈酸锶显示出相对良好的耐受性，安全性良好。雷奈酸锶应被视为绝经后骨质疏松症患者的一线治疗药物。
